NDAVAGINALGEL
Approved
May 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
VANDAZOLE (metronidazole) by Teva is 12. Approved for complicated intra-abdominal infection, bacterial vaginosis, rosacea and 2 more indications. First approved in 2005.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANDAZOLE is a topical metronidazole gel (1%) approved for vaginal bacterial vaginosis and rosacea. It is a nitroimidazole antimicrobial with a mechanism of action in rosacea that remains unknown. The drug has minimal systemic absorption when applied topically, with plasma concentrations <1% of oral dosing.
$0.269MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Medicare claims volume, signaling a contracting brand team and limited career growth opportunities.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of metronidazole in the treatment of rosacea is unknown. 12.2 Pharmacodynamics The pharmacodynamics of metronidazole in association with the treatment of rosacea are unknown. Cardiac Electrophysiology: The effect of Metronidazole Gel, 1% on the QTc…
Pharmacologic Class:
Nitroimidazole Antimicrobial
Indications (5)
Worked on VANDAZOLE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.